Stock listing
Stockholm:ACE Ascelia Pharma AB Aktie
Home listing (Stockholm) of Ascelia Pharma AB
Follow Ascelia Pharma AB into a list and get an email when it puts out news.
Share price · OMXSTO:ACE
0.559 SEK -0.039 (-6.5%)
Close on Nov 20, 2026
- Day range
- 0.553 – 0.592 SEKNov 20, 2026
- Volume
- 164,727 sharesNov 20, 2026
- Market cap
- 74.65M SEKAt the close on Nov 20, 2026 · price × 133.5M shares outstanding
- 52-week range
- 0.455 – 3.550 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 630,549 SEKMedian day 601,712 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:ACE · Home | 0.559 SEK | -0.039 (-6.5%) | 164,727 | 0.591 | 0.592 | 0.553 | 0.598 | Close on Nov 20, 2026 |
| Frankfurt:7ZA | €0.042 EUR | -0.004 (-8.1%) | — | €0.045 | €0.045 | €0.042 | €0.046 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:ACE · SEK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 0.559 | -0.039 | -6.5% | 0.591 | 0.592 | 0.553 | 164,727 | |
| 0.598 | +0.024 | +4.2% | 0.574 | 0.600 | 0.560 | 319,076 | |
| 0.574 | -0.026 | -4.3% | 0.600 | 0.600 | 0.560 | 83,660 | |
| 0.600 | +0.020 | +3.4% | 0.580 | 0.610 | 0.523 | 602,521 | |
| 0.580 | +0.047 | +8.8% | 0.533 | 0.590 | 0.519 | 539,288 | |
| 0.533 | +0.013 | +2.5% | 0.519 | 0.533 | 0.519 | 276,377 | |
| 0.520 | -0.038 | -6.8% | 0.521 | 0.534 | 0.516 | 124,143 | |
| 0.558 | 0.000 | 0.0% | 0.559 | 0.610 | 0.524 | 1,229,881 | |
| 0.558 | +0.047 | +9.2% | 0.521 | 0.761 | 0.520 | 3,431,685 | |
| 0.511 | -0.027 | -5.0% | 0.538 | 0.549 | 0.508 | 885,584 | |
| 0.538 | -0.018 | -3.2% | 0.542 | 0.550 | 0.530 | 111,597 | |
| 0.556 | -0.024 | -4.1% | 0.580 | 0.580 | 0.521 | 319,481 | |
| 0.580 | 0.000 | 0.0% | 0.580 | 0.588 | 0.550 | 157,034 | |
| 0.580 | +0.065 | +12.6% | 0.522 | 0.588 | 0.514 | 768,378 | |
| 0.515 | -0.005 | -1.0% | 0.518 | 0.532 | 0.512 | 261,963 | |
| 0.520 | -0.008 | -1.5% | 0.541 | 0.541 | 0.517 | 422,042 | |
| 0.528 | +0.008 | +1.5% | 0.520 | 0.550 | 0.511 | 243,966 | |
| 0.520 | +0.010 | +2.0% | 0.520 | 0.540 | 0.510 | 176,030 | |
| 0.510 | +0.004 | +0.8% | 0.512 | 0.570 | 0.510 | 600,903 | |
| 0.506 | -0.012 | -2.3% | 0.519 | 0.579 | 0.504 | 480,174 | |
| 0.518 | -0.017 | -3.2% | 0.535 | 0.535 | 0.507 | 460,192 | |
| 0.535 | -0.027 | -4.8% | 0.562 | 0.635 | 0.535 | 1,086,850 | |
| 0.562 | +0.024 | +4.5% | 0.539 | 0.580 | 0.539 | 495,089 | |
| 0.538 | -0.042 | -7.2% | 0.571 | 0.571 | 0.510 | 1,414,855 | |
| 0.580 | -0.095 | -14.1% | 0.649 | 0.649 | 0.580 | 1,285,125 | |
| 0.675 | -0.005 | -0.7% | 0.680 | 0.693 | 0.601 | 1,085,173 | |
| 0.680 | -0.180 | -20.9% | 0.650 | 0.703 | 0.510 | 4,584,675 | |
| 0.860 | +0.004 | +0.5% | 0.838 | 0.898 | 0.800 | 1,569,400 | |
| 0.856 | +0.156 | +22.3% | 0.701 | 0.890 | 0.701 | 1,914,185 | |
| 0.700 | -0.102 | -12.7% | 0.802 | 0.802 | 0.700 | 756,786 | |
| 0.802 | -0.018 | -2.2% | 0.844 | 0.844 | 0.782 | 870,590 | |
| 0.820 | +0.010 | +1.2% | 0.841 | 0.934 | 0.800 | 3,460,165 | |
| 0.810 | +0.011 | +1.4% | 0.799 | 0.855 | 0.799 | 1,238,986 | |
| 0.799 | +0.007 | +0.9% | 0.787 | 0.914 | 0.772 | 2,627,116 | |
| 0.792 | +0.161 | +25.5% | 0.635 | 1.058 | 0.631 | 6,108,157 | |
| 0.631 | -0.016 | -2.5% | 0.646 | 0.653 | 0.620 | 745,979 | |
| 0.647 | +0.004 | +0.6% | 0.643 | 0.662 | 0.630 | 471,060 | |
| 0.643 | +0.014 | +2.2% | 0.629 | 0.644 | 0.602 | 455,596 | |
| 0.629 | +0.009 | +1.5% | 0.601 | 0.645 | 0.601 | 331,322 | |
| 0.620 | 0.000 | 0.0% | 0.620 | 0.627 | 0.585 | 457,906 | |
| 0.620 | +0.012 | +2.0% | 0.608 | 0.639 | 0.597 | 203,713 | |
| 0.608 | -0.018 | -2.9% | 0.627 | 0.650 | 0.600 | 638,607 | |
| 0.626 | +0.053 | +9.2% | 0.593 | 0.649 | 0.573 | 372,777 | |
| 0.573 | -0.029 | -4.8% | 0.615 | 0.615 | 0.571 | 329,679 | |
| 0.602 | -0.020 | -3.2% | 0.600 | 0.632 | 0.600 | 313,194 | |
| 0.622 | +0.003 | +0.5% | 0.617 | 0.629 | 0.590 | 441,588 | |
| 0.619 | -0.018 | -2.8% | 0.644 | 0.651 | 0.612 | 315,917 | |
| 0.637 | -0.005 | -0.8% | 0.640 | 0.670 | 0.624 | 558,050 | |
| 0.642 | -0.016 | -2.4% | 0.659 | 0.659 | 0.631 | 478,183 | |
| 0.658 | +0.013 | +2.0% | 0.645 | 0.659 | 0.638 | 377,243 | |
| 0.645 | +0.003 | +0.5% | 0.630 | 0.648 | 0.620 | 785,205 | |
| 0.642 | 0.000 | 0.0% | 0.642 | 0.642 | 0.642 | 739,283 | |
| 0.642 | +0.012 | +1.9% | 0.637 | 0.646 | 0.621 | 250,012 | |
| 0.630 | +0.023 | +3.8% | 0.607 | 0.637 | 0.600 | 828,846 | |
| 0.607 | -0.008 | -1.3% | 0.615 | 0.615 | 0.582 | 1,068,956 | |
| 0.615 | -0.016 | -2.5% | 0.630 | 0.634 | 0.591 | 897,025 | |
| 0.631 | 0.000 | 0.0% | 0.614 | 0.631 | 0.611 | 351,955 | |
| 0.631 | +0.008 | +1.3% | 0.603 | 0.632 | 0.603 | 683,348 | |
| 0.623 | -0.003 | -0.5% | 0.631 | 0.639 | 0.603 | 1,527,374 | |
| 0.626 | +0.018 | +3.0% | 0.624 | 0.638 | 0.610 | 677,149 | |
| 0.608 | -0.007 | -1.1% | 0.615 | 0.640 | 0.606 | 2,043,032 | |
| 0.615 | +0.005 | +0.8% | 0.610 | 0.650 | 0.598 | 2,270,121 | |
| 0.610 | +0.020 | +3.4% | 0.570 | 0.617 | 0.561 | 1,142,953 | |
| 0.590 | +0.040 | +7.3% | 0.598 | 0.598 | 0.553 | 748,708 |
- Ticker
- Stockholm:ACE
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stockholm
- Currency
- SEK
What changed lately
Latest news release · Sep 24, 2026
Ascelia Pharma Announces Publication of Orviglance Clinical Study in Journal of Magnetic Resonance Imaging
Latest earnings call · Aug 20, 2026
Ascelia Pharma (Stockholm:ACE) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Aug 20, 2026
Q2 2026 Earnings Presentation
Earnings · 24 slides
Latest news
Ascelia Pharma Announces Publication of Orviglance Clinical Study in Journal of Magnetic Resonance Imaging
Sep 24, 2026
Closed 0.629 (+1.5%) on Sep 24, 2026
Ascelia Pharma Completes FDA Type A Meeting on Orviglance NDA
Sep 10, 2026
Closed 0.642 (-2.4%) on Sep 10, 2026
Ascelia Pharma Announces FDA Has Scheduled Type A Meeting for Orviglance NDA on September 9, 2026
Aug 17, 2026
Closed 0.60 (+4.3%) on Aug 17, 2026
Ascelia Pharma Announces Organizational Changes and a Reduced Cost Base
Jul 15, 2026
Closed 0.509 (+7.2%) on Jul 15, 2026
Ascelia Pharma Provides Update on the Orviglance NDA
Jul 3, 2026
Closed 0.808 (-75.4%) on Jul 3, 2026
Ascelia Pharma Expands Orviglance IP Portfolio with New Patent Filing
Jun 30, 2026
Closed 2.96 (+1.0%) on Jun 30, 2026
Ascelia Pharma Carries Out a Directed Share Issue of SEK 20 Million
Apr 23, 2026
Closed 3.15 (-2.3%) on Apr 24, 2026
Notice of Annual General Meeting in Ascelia Pharma AB
Mar 30, 2026
Closed 2.89 (+5.9%) on Mar 31, 2026
Ascelia Pharma Announces Acceptance of Orviglance Data for Oral Presentation at the Annual Radiology Congress ESGAR 2026
Mar 27, 2026
Closed 2.89 (-2.5%) on Mar 27, 2026
Ascelia Pharma Announces Deputy CEO Julie Waras Brogren to Leave the Company
Jan 21, 2026
Closed 2.83 (-10.9%) on Jan 21, 2026
Ascelia Pharma AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 12 in the last 12 months · 19 in all · newest Sep 24, 2026 · oldest 2025
- Calls
- 10 calls with a replay · 10 with a transcript · latest Aug 20, 2026
- Decks
- 8 decks · latest Aug 20, 2026
Where Ascelia Pharma AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:ACE · Home listing · This page | Stockholm | Sweden | SEK |
| Aquis:ACES | Aquis | United Kingdom | SEK |
| Aquis:ACES | Aquis | United Kingdom | SEK |
| Frankfurt:7ZA | Frankfurt | Germany | EUR |
Valuation
Price/book 0.8× against a median of 2.4×: 4th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 37.09M SEK
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.8×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Ascelia Pharma AB · OMXSTO:ACE | US$7.30M | US$3.63M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | n/a |
| Annexin Pharmaceuticals AB · OMXSTO:ANNX | US$7.59M | US$6.18M | n/a | n/a | n/a | 6.3× | n/a | 0.0× | n/a |
| Solvonis Therapeutics PLC · LSE:SVNS | US$7.57M | US$6.80M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | n/a |
| Vistagen Therapeutics, Inc. · NASDAQ:VTGN | US$7.56M | −US$11.87M | n/a | −5.0× | n/a | 0.5× | n/a | 0.0× | 1.47 |
| Noxopharm Ltd. · ASX:NOX | US$7.52M | US$10.36M | n/a | 11.0× | n/a | n/a | −312.2% | n/a | n/a |
| AEON Biopharma, Inc. · AMEX:AEON | US$7.27M | −US$4.15M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 1.04 |
| Pila Pharma AB · OMXSTO:PILA | US$7.01M | US$6.70M | n/a | n/a | n/a | 4.5× | n/a | 0.0× | n/a |
| Cadrenal Therapeutics, Inc. · NASDAQ:CVKD | US$7.01M | US$3.95M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.60 |
| Ensysce Biosciences, Inc. · NASDAQ:ENSC | US$7.00M | −US$22.51M | n/a | −3.6× | n/a | 0.3× | n/a | 0.0× | 1.28 |
| Arctic Bioscience AS · OSL:ABS | US$7.00M | US$11.38M | n/a | 2.8× | n/a | 0.4× | −102.3% | 0.3× | n/a |
| Alaunos Therapeutics, Inc. · NASDAQ:TCRT | US$6.99M | US$6.37M | n/a | 2,124× | n/a | 7.2× | n/a | 0.0× | 0.90 |
| Median of the others | US$7.14M | US$6.27M | 2.8× | 2.4× | −207.2% | 0.0× | 1.28 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.93 SEK · Analysts' mean
- EPS, year to Dec 2026
- -0.13 · 2 analysts
- Revenue, year to Dec 2026
- 26M · 3 analysts
Team and board
| Officer | Role |
|---|---|
| Jennie Wilborgsson | Chief Operating Officer |
Events
Calls
| Call | When | Status |
|---|---|---|
| Ascelia Pharma (Stockholm:ACE) Q2 2026 Earnings Call | Thu, Aug 20, 2026 · 4:00 AM ET | Replay |
| Ascelia Pharma (Stockholm:ACE) Q1 2026 Earnings Call | Tue, May 12, 2026 · 4:00 AM ET | Replay |
| Ascelia Pharma (Stockholm:ACE) Q4 2025 Earnings Call | Thu, Feb 05, 2026 · 4:00 AM ET | Replay |
| Ascelia Pharma (Stockholm:ACE) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 4:00 AM ET | Replay |
| Ascelia Pharma (Stockholm:ACE) Q2 2025 Earnings Call | Fri, Aug 22, 2025 · 4:00 AM ET | Replay |
| Ascelia Pharma (Stockholm:ACE) Q1 2025 Earnings Call | Fri, May 16, 2025 · 4:00 AM ET | Replay |
| Ascelia Pharma (Stockholm:ACE) Q4 2024 Earnings Call | Fri, Feb 07, 2025 · 4:00 AM ET | Replay |
| Ascelia Pharma (Stockholm:ACE) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 4:00 AM ET | Replay |
| Ascelia Pharma (Stockholm:ACE) Q2 2024 Earnings Call | Thu, Aug 15, 2024 · 4:00 AM ET | Replay |
| Ascelia Pharma (Stockholm:ACE) Q1 2024 Earnings Call | Thu, May 16, 2024 · 4:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Feb 5, 2026 · Before open | +6.0% |
| Q3 2025 | Nov 5, 2025 · Before open | −1.9% |
| Q2 2025 | Aug 21, 2025 · Before open | +3.7% |
| Q1 2025 | May 16, 2025 · Before open | −2.1% |
| Q4 2024 | Feb 7, 2025 · Before open | +5.6% |
| Q3 2024 | Nov 7, 2024 · Before open | +12.9% |
| Q2 2024 | Aug 15, 2024 · Before open | +14.5% |
| Q1 2024 | May 16, 2024 · Before open | −6.7% |
| Q4 2023 | Feb 9, 2024 · Before open | −4.8% |
| Q3 2023 | Nov 8, 2023 · Before open | +2.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Aug 18, 2023 · Before open | −5.5% |
| Q1 2023 | May 11, 2023 · Before open | −1.5% |
| Q4 2022 | Feb 10, 2023 · After close | +0.8% |
| Q3 2022 | Nov 4, 2022 · Before open | +10.7% |
| Q2 2022 | Aug 18, 2022 · Before open | −2.6% |
| Q1 2022 | May 11, 2022 · Before open | −3.1% |
| Q4 2021 | Feb 10, 2022 · Before open | +1.6% |
| Q3 2021 | Nov 4, 2021 · Before open | +4.6% |
| Quarter to Jun 30, 2021 | Aug 19, 2021 · Before open | −4.8% |
| Quarter to Mar 31, 2021 | May 12, 2021 · Before open | −0.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 24 slides | Aug 20, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 23 slides | Feb 5, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 30 slides | Nov 5, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 26 slides | Aug 22, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 29 slides | May 16, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 33 slides | Nov 7, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 30 slides | Aug 15, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 40 slides | May 16, 2024 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of ordinary shares Announced: SEK 20M · SEK 3 a share · ABG Sundal Collier AB Dealers: ABG Sundal Collier AB Buyers: Salenia AB (existing shareholder); Mats Thorén (existing shareholder); Fredrik Lundgren; Wilhelm Risberg Use of proceeds: Strengthen the balance sheet, enhance its position in partnering discussions for Orviglance and extend the cash runway into 2027 | Apr 23, 2026 | US$2.17M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 888.0K | 938.0K | 1.05M | 3.89M | 8.72M | 825.0K | 62.0K | 2.51M | |
| Gross profit | 0 | 0 | 0 | 0 | 0 | -825.0K | -62.0K | -2.51M | |
| Research and development | 56.8M | 50.8M | 81.3M | 118.1M | 107.6M | 64.8M | 26.9M | 15.6M | 9.37M |
| Selling, general and administrative | 6.48M | 18.0M | 19.8M | 14.6M | 8.81M | 18.3M | 18.0M | 6.59M | 16.4M |
| Operating income | -74.4M | -67.8M | -110.9M | -147.0M | -137.9M | -93.4M | -36.7M | -37.4M | -24.7M |
| Depreciation and amortization | 888.0K | 938.0K | 1.05M | 1.05M | 1.03M | 825.0K | 62.0K | 5.00K | 24.7M |
| EBITDA | -73.5M | -66.8M | -109.9M | -146.0M | -136.9M | -92.6M | -36.7M | -37.4M | -42.0K |
| Interest expense | 5.51M | 13.9M | 2.42M | 3.96M | 2.01M | 13.0K | 0 | 33.0K | 18.0K |
| Income before tax | -76.7M | -80.1M | -109.6M | -133.2M | -129.5M | -99.7M | -40.0M | -37.6M | -24.7M |
| Income tax | -468.0K | -94.0K | -319.0K | -1.93M | -3.62M | -1.05M | -90.0K | -417.0K | -351.0K |
| Net income | -76.3M | -80.0M | -109.3M | -131.2M | -125.9M | -98.7M | -39.9M | -37.1M | -24.4M |
| Earnings per share, basic | -0.67 | -1.48 | -3.24 | -3.77 | -3.82 | -3.76 | -1.83 | -2.16 | -1.08 |
| Earnings per share, diluted | -0.67 | -1.48 | -3.24 | -3.77 | -3.82 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 49.9M | 75.3M | 21.9M | 149.6M | 261.6M | 184.7M | 108.5M | 150.0M | 55.1M | 1.63M |
| Short-term investments | 1.00K | 0 | 75.7M | 75.1M | -47.0K | |||||
| Receivables | 3.93M | 5.68M | 580.0K | 4.53M | 5.56M | 2.83M | 1.42M | 3.93M | 1.06M | 20.5M |
| Inventory | -6.08M | 6.79M | 8.28M | 2.96M | -20.5M | |||||
| Current assets | 53.9M | 83.7M | 28.9M | 160.9M | 274.6M | 196.3M | 192.9M | 230.1M | 59.1M | 23.3M |
| Property, plant and equipment | 52.0K | 15.0K | 89.0K | 163.0K | 238.0K | 1.99M | 212.0K | 275.0K | 0 | |
| Goodwill | -57.0M | |||||||||
| Total assets | 111.9M | 140.9M | 87.1M | 218.6M | 333.5M | 255.4M | 250.2M | 287.4M | 116.1M | 80.4M |
| Accounts payable | 2.04M | 4.73M | 1.52M | 15.9M | 6.15M | 3.88M | 5.24M | 4.27M | 634.0K | 643.0K |
| Current liabilities | 12.4M | 62.0M | 12.6M | 37.5M | 25.1M | 18.4M | 13.1M | 11.2M | 4.42M | 2.79M |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 1.04M | 25.4M | 1.06M | 484.0K | 1.66M | 1.78M | 215.0K | 146.0K | ||
| Total liabilities | 12.5M | 62.0M | 12.7M | 37.7M | 25.7M | 19.3M | 13.2M | 11.3M | 4.42M | 2.79M |
| Shareholders' equity | 99.5M | 78.9M | 74.3M | 180.9M | 307.8M | 236.1M | 237.1M | 276.1M | 111.7M | 77.6M |
| Shares outstanding | 113.4M | 54.0M | 33.7M | 34.8M | 33.0M | 26.3M | 21.8M | 17.2M | 22.6M | 22.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -72.3M | -62.8M | -126.8M | -125.3M | -116.6M | -85.5M | -36.9M | -30.3M | -21.0M |
| Capital spending | -57.0K | 0 | 0 | 0 | -38.0K | -397.0K | -397.0K | -397.0K | -397.0K |
| Free cash flow | -72.3M | -62.8M | -126.8M | -125.3M | -116.6M | -85.9M | -36.9M | -30.3M | -21.0M |
| Cash from investing | -57.0K | 0 | 47.0K | -65.0K | -38.0K | 76.0M | -75.0K | -75.0M | -75.0M |
| Cash from financing | 48.2M | 115.2M | -936.0K | -1.10M | 184.9M | 92.7M | -60.0K | 200.2M | 74.4M |
| Share buybacks | 72.8M | 105.3M | -89.0K | -295 | -397.0K | 98.7M | 0 | 222.1M | 80.4M |
| Change in cash | -24.1M | 52.3M | -127.7M | -126.4M | 68.3M | 76.2M | 53.5M | 94.9M | 53.4M |
Cap table
Built by 6ix from Ascelia Pharma AB’s releases · as of Apr 23, 2026
- Common shares
- 133,535,460
- Fully diluted
- 133,535,460
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 133,535,460 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 133,535,460 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jennie Wilborgsson | Chief Operating Officer · Since at least Nov 3, 2025 |
Log in to ask 6ix AI your own questions about Ascelia Pharma AB.